Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

150.10USD
4:00pm EDT
Change (% chg)

$-0.51 (-0.34%)
Prev Close
$150.61
Open
$150.32
Day's High
$150.62
Day's Low
$148.85
Volume
88,966
Avg. Vol
177,337
52-wk High
$163.69
52-wk Low
$95.80

Latest Key Developments (Source: Significant Developments)

Jazz pharmaceuticals announces Q1 2017 financial results
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Jazz Pharmaceuticals PLC ::Jazz pharmaceuticals announces first quarter 2017 financial results.Q1 adjusted earnings per share $2.31.Q1 GAAP earnings per share $1.41.Q1 revenue $376 million versus I/B/E/S view $377 million.Q1 earnings per share view $2.34 -- Thomson Reuters I/B/E/S.Sees 2017 total net product sales $1,617 million to $1,692 million.Sees 2017 GAAP net income per diluted share $6.55-$7.55.Sees 2017 non-gaap adjusted net income per diluted share $10.70-$11.30.FY2017 earnings per share view $11.12, revenue view $1.67 billion -- Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals announces positive results of JZP-110 study
Wednesday, 26 Apr 2017 04:05pm EDT 

April 26 (Reuters) - Jazz Pharmaceuticals Plc :Jazz Pharmaceuticals announces positive results from the phase 3 tones 2 study of jzp-110 in narcolepsy patients with excessive sleepiness.Says expect to submit JZP-110 nda for excessive sleepiness in obstructive sleep apnea and narcolepsy in late 2017.Jazz Pharmaceuticals - most commonly reported AEs in study generally consistent with those observed in phase 2 clinical studies evaluating JZP-110.Says JZP-110 75 mg dose reached statistical significance on co-primary endpoint of mwt.Says JZP-110 75 mg dose did not reach statistical significance on co-primary endpoint of ess.Jazz Pharmaceuticals - there was one patient with two saes on JZP-110 that were considered not treatment related as assessed by investigator.  Full Article

Jazz Pharmaceuticals reports psoitive data from phase 2/3 study of Xyrem
Monday, 24 Apr 2017 04:05pm EDT 

April 24 (Reuters) - Jazz Pharmaceuticals Plc -:Jazz Pharmaceuticals announces positive results from the phase 2/3 express study of xyrem in pediatric patients with narcolepsy with cataplexy.Jazz Pharmaceuticals Plc - xyrem demonstrated statistically significant differences in primary and key secondary efficacy endpoints.Jazz Pharmaceuticals - preliminary safety results consistent with results observed in xyrem studies in adults and xyrem post-marketing experience.  Full Article

BRIEF-Hikma enters into settlement agreement with Jazz
Thursday, 6 Apr 2017 02:00am EDT 

Hikma Pharmaceuticals Plc : Hikma enters into settlement agreement with Jazz . Enters into settlement agreement with Jazz for sodium oxybate . Announces that it has entered into a settlement agreement with Jazz Pharmaceuticals Plc . Settlement that resolves patent litigation related to Jazz's xyrem (sodium oxybate) oral solution, 500mg/ml product . Under settlement agreement, Jazz will grant Hikma, right to sell an authorised generic of xyrem in US market commencing on 1 Jan 2023 or earlier under certain circumstances . Initial term of AG arrangement is six months and Hikma has option to extend AG term for up to a total of five years . Jazz has also granted Hikma a licence to market generic sodium oxybate pursuant to its anda at end of AG term . Hikma will pay Jazz a royalty on net sales of AG product, but will initially retain a meaningful percentage of net sales . Royalty rate paid to Jazz will increase should AG term be extended beyond one year .Specific financial and other terms related to settlement agreement are confidential.  Full Article

Jazz Pharma says gave Roxane non-exclusive license under Xyrem patents to produce generic sodium oxybate product
Wednesday, 5 Apr 2017 05:54pm EDT 

Jazz Pharmaceuticals Plc :Jazz Pharma - also gave Roxane non-exclusive license under Xyrem patents to make, market its generic sodium oxybate product under Roxane ANDA in Territory.  Full Article

Jazz Pharma settles Xyrem patent litigation with Hikma Pharma
Wednesday, 5 Apr 2017 04:30pm EDT 

Jazz Pharmaceuticals Plc : Jazz Pharmaceuticals reaches settlement with Hikma Pharmaceuticals related to Xyrem patent litigation . Jazz pharmaceuticals - initial term of AG arrangement is six months, Hikma has option to continue sale of AG product for up to a total of five years . Jazz pharmaceuticals- in connection with settlement, co granted Hikma and its unit right to sell authorized generic version of Xyrem in U.S. under Xyrem NDA . Jazz pharmaceuticals plc - specific financial and other terms related to ag product are confidential . Jazz Pharmaceuticals Plc - Hikma has been granted a license to sell its generic sodium Oxybate product under its ANDA at end of AG term . Jazz Pharmaceuticals - co to receive meaningful royalty on net sales of AG product,with royalty rate increasing during initial AG term based on ag sales . Jazz Pharmaceuticals - Jazz to be paid for supply of AG product, to be reimbursed for portion of service costs associated with operation of Xyrem REMS .Jazz Pharmaceuticals- Jazz will also be reimbursed for a portion of service costs associated with distribution of AG.  Full Article

Jazz Pharmaceuticals Q4 adj earnings per share $2.71
Tuesday, 28 Feb 2017 04:05pm EST 

Jazz Pharmaceuticals Plc : Jazz Pharmaceuticals Plc sees 2017 revenues $1,625-$1,700 million . Jazz Pharmaceuticals Plc sees 2017 total net product sales $1,617-$1,692 million . Jazz Pharmaceuticals Plc sees 2017 GAAP net income per diluted share $6.55-$7.55 . Jazz Pharmaceuticals Plc sees 2017 NON-GAAP adjusted net income per diluted share $10.70-$11.30 . FY2017 earnings per share view $11.33, revenue view $1.68 billion -- Thomson Reuters I/B/E/S . Jazz pharmaceuticals announces full year and fourth quarter 2016 financial results . Q4 adjusted earnings per share $2.71 . Q4 GAAP earnings per share $1.91 .Q4 earnings per share view $2.65 -- Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease
Wednesday, 8 Feb 2017 04:05pm EST 

Jazz Pharmaceuticals Plc : Jazz Pharmaceuticals announces first patient enrolled in Phase 2 clinical study evaluating JZP-110 for excessive sleepiness in Parkinson's disease .Jazz Pharmaceuticals Plc- Study is expected to enroll approximately 50 patients for phase 2 clinical study evaluating JZP-110.  Full Article

Jazz Pharmaceuticals comments on FDA nod for generic version of Xyrem
Wednesday, 18 Jan 2017 06:24am EST 

Jazz Pharmaceuticals Plc : Jazz Pharmaceuticals says it will evaluate FDA's waiver of requirement for a single, shared system rems in connection with approval of a generic version of Xyrem . Says it will evaluate whether FDA's waiver meets conditions for such a waiver under applicable law .Says it intends to evaluate potential challenges to FDA's waiver decision on the generic version of Xyrem.  Full Article

Jazz Pharma Q2 adjusted earnings per share $2.63
Tuesday, 9 Aug 2016 04:05pm EDT 

Jazz Pharmaceuticals Plc : Jazz pharmaceuticals announces second quarter 2016 financial results . Q2 gaap earnings per share $1.80 . Updated financial guidance for 2016. . Q2 adjusted earnings per share $2.63 . Q2 earnings per share view $2.80 -- Thomson Reuters I/B/E/S . Sees 2016 gaap net income per diluted share $5.66-$6.56 . Fy2016 earnings per share view $11.14, revenue view $1.52 billion -- Thomson Reuters I/B/E/S . Q2 revenue view $376.4 million -- Thomson Reuters I/B/E/S . Qtrly total revenues $381.2 million versus $333.7 million . Sees 2016 revenue $1,485 million to $1,530 million .Sees 2016 non-gaap adjusted net income per diluted share $9.90-$10.30.  Full Article

More From Around the Web

BRIEF-Jazz Pharma to present key data on sleeping disorder drug at meeting

* Jazz pharmaceuticals to present phase 3 data on jzp-110, an investigational treatment for excessive sleepiness in patients with narcolepsy and with obstructive sleep apnea, during 31st annual sleep meeting Source text for Eikon: Further company coverage: